2024-03-28
Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future
Viva Biotech will continue to advance the integrated CRO-CDMO strategy, aiming to establish comprehensive and comprehensive FIC drug development servi